Dr. Leclerc is investigating the role of the Receptor for Advanced Glycation End Products (RAGE) in progression and metastasis of pancreatic cancer. Her group is focused on blocking the activation of RAGE by monoclonal antibodies as a therapeutic tool for pancreatic cancer.
Dr. Liu has been interested in developing nanomaterial-based platforms for early detection of pancreatic cancer. His group is involved in developing fast, sensitive, and cost-effective lateral-flow devices for detection of protein and micro-RNA biomarkers present in bodily fluids of pancreatic cancer patients.
Mohi Quadir is aiming to develop spatially and temporally-responsive drug delivery nano carriers for pancreatic cancer. The Quadir group is involved in designing linear and dendritic block copolymers that forms nano-sized polymersomes and vesicles capable of encapsulating frontline chemotherapeutic agents and trafficking them to specific cellular compartments without triggering off-target toxicity.
Dr. Reindl’s research is focused on the roles of small molecule phytochemicals (e.g., piperlongumin) in inducing oxidative stress which kills K-ras oncogene harboring pancreatic cancer cells. The mechanistic details, as well as therapeutic potentials of piperlongumin in combination of gemcitabine, are being investigated at both cellular and model animal levels.